A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

Journal of Pediatrics

Volumn 139, Issue 6, 2001, Pages 813-820

  Quan, Joanne M ^{a,b,c,d,e,f,g}   Tiddens, Harm A W M ^{a,b,c,d,e,f,g}   Sy, Judy P ^{a,b,c,d,e,f,g}   McKenzie, Sheila G ^{a,b,c,d,e,f,g}   Montgomery, Mark D ^{a,b,c,d,e,f,g}   Robinson, Philip J ^{a,b,c,d,e,f,g}   Wohl, Mary Ellen B ^{a,b,c,d,e,f,g}   Konstan, Michael W ^{a,b,c,d,e,f,g}  

^a GENENTECH INC   (United States)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d ALBERTA CHILDREN'S HOSPITAL   (Canada)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DORNASE ALFA; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; CHILD; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LARYNGITIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SPIROMETRY; THORAX PAIN; TREATMENT OUTCOME;

EID: 0035666058     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2001.118570     Document Type: Article

References (30)

1. Cystic fibrosis
2. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis
3. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis
4. Early pulmonary inflammation in infants with cystic fibrosis
5. Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: A bronchoscopic study
6. Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology
7. Lower airway inflammation in infants and young children with cystic fibrosis
8. Pediatric pulmonary disease: Assessment with high-resolution ultrafast CT
9. Total respiratory system compliance in asymptomatic infants with cystic fibrosis
10. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis
11. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum
12. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
13. Pulmonary function between 6 and 18 years of age
14. Standardization of spirometry-1994 update
15. Evaluation of scoring system of the chest radiograph in cystic fibrosis: A collaborative study
16. Changes in the maximal expiratory flow-volume curve with growth and aging
17. Physical growth: National Center for Health Statistics percentiles
18. Nonparametric estimation from incomplete observations
19. Regression models and life tables
20. Acute effects of ozone on the pulmonary function of exercising school children from Mexico City
21. Effects of cigarette smoking on lung function in adolescent boys and girls
22. Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the US and Canada
23. 1 decline in children and adolescents with cystic fibrosis: Effect of predicted equations
24. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
25. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease
26. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation
27. Effect of high-dose ibuprofen in patients with cystic fibrosis
28. Improved survival in the Danish center-treated cystic fibrosis patients: Results of aggressive treatment